A team of researchers from The Netherlands recently discovered that talc (magnesium silicate), often used in the food industry, is a danger to health and exposure to it should be closely monitored. The study findings were recently presented by Dr. Jos Rooijackers, a pulmonologist from the Netherlands Expertise Centre for…
In a new study entitled “BARD1 mediates TGF-β signaling in pulmonary fibrosis”, researchers investigated whether the tumor suppressor gene BARD1, previously shown to have a role in lung cancer, is associated with pulmonary fibrosis. They found that TGF-beta, an established factor in promoting fibrosis, induces BARD1 protein expression…
New data from the analysis of trial INPULSIS™-ON, describing the long-term efficacy and side-effects of OFEV in the treatment of idiopathic pulmonary fibrosis (IPF), was presented at the European Respiratory Society (ERS) International Congress 2015. IPF is a type of interstitial lung disease, affecting the tissue that supports the alveoli…
Sixty-six year old Dan Castner was living life to the fullest when he started experiencing difficulties in breathing. While he worked in the outdoor industry for more than 40 years and was used to biking, climbing, camping, skiing and hiking, in March of 2012 his life completely changed. Castner was diagnosed with…
A new study recently published in the journal Respiratory Research revealed that a uridine-based therapy can improve pulmonary fibrosis symptoms in a mouse model. The study is entitled “Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis,” and was…
A team of researchers from the Department of Clinical and Experimental Medicine at the University of Catania, Italy recently reviewed the co-occurrence of additional diseases in Idiopathic Pulmonary Fibrosis and their current therapeutic strategies. The study, entitled “IPF, comorbidities and management implications,“ was published in the Sarcoidosis Vasculitis and…
The National Institutes of Health (NIH) recently awarded a Yale University scientist with a $3 million dollar research grant to help fund his work on exploring the molecular networks that underlie the histological features of idiopathic pulmonary fibrosis (IPF). The research project hopes to offer new insights into the disease and lead to the discovery…
Reata Pharmaceuticals recently announced that results of a Phase 2 study of bardoxolone methyl in patients suffering from pulmonary arterial hypertension (PAH) will be presented at the 2015 American College of Chest Physicians (CHEST) annual meeting at the Palais des Congrès de Montréal, Canada. The presentation, entitled “Initial Data Report from…
In a newly published paper in the Stem Cells Translational Medicine journal entitled Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis, scientists from North Carolina State University discovered a quick and simple method to produce stem…
MediciNova, Inc., a biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the US Food and Drug Administration has granted its leading product candidate for idiopathic pulmonary fibrosis (IPF) a Fast Track Designation. This follows the agency’s October 2014 decision to grant…
Get regular updates to your inbox.
